Background: Withania somnifera (L.) Dunal roots are known for their anti-inflammatory and rejuvenative properties. This study focuses on the growth inhibitory activity of W. somnifera root extracts against some bacterial triggers of autoimmune inflammatory diseases, as well as the extracts in combination with conventional antibiotics. Methods: W. somnifera root powder was extracted with solvents of varying polarity and screened for inhibition of bacterial growth. Inhibition on agar was assessed by disc diffusion techniques, whilst the minimum inhibitory concentrations (MICs) were quantified by liquid dilution assays. To screen for combinatorial effects, the W. somnifera root extracts were combined with a range of conventional antibiotics and tested against each bacterial strain using liquid dilution assays. Extract toxicities was examined using Artemia nauplii bioassays, while their phytochemical profiles were determined using standard methodologies. Results: W. somnifera root extracts were unable to inhibit the growth of P. mirabilis, K. pneumonia, A. baylyi and Pseudomonas aeruginosa. However, the methanolic and aqueous extracts were good inhibitors of Y. enterocolitica, with MICs of 696 and 358 μg/mL respectively. These extracts also inhibited S. pyogenes growth, albeit with substantially higher MIC values indicative of only mild inhibition. Only small zones of inhibition were observed on agar for these extracts against both strains. Combinations of the W. somnifera extracts and conventional antibiotics generally produced additive or indifferent interactions, indicating that they are safe to use concomitantly without compromising the efficacy of either component. A single antagonistic combination (aqueous extract and tetracycline) against Y. enterocolitica was observed. All extracts were determined to be non-toxic as assessed in Artemia nauplii bioassays. Conclusions: Methanolic and aqueous W. somnifera extracts were strong inhibitors of Y. enterocolitica growth and mild inhibitors of S. pyogenes. These extracts were also non-toxic in the Artemia nauplii bioassay, indicating their potential for the prevention and treatment of Hashimoto's disease.
INTRODUCTION
In recent years, there has been an increase in bacterial resistance to many conventional antibiotics and several strains of medicinally important bacterial pathogens are now multi (MDR), extensively (XDR) or totally drug resistant (TDR). 1 There are now limited therapeutic options for the diseases caused by these pathogens. This problem is expected to be exacerbated in the future as bacteria exchange resistance genes and more strains develop MDR. The development of alternative anti bacterial treatment modalities has become crucial and is considered by the World Health Organisation (WHO) to be one of the most serious challenges facing medical science. 2 For a number of reasons (reviewed elsewhere), 1 it is unlikely that the previous methods of antibiotic discovery/ development will be as successful in the future and new treatment modalities are urgently required. Traditional medicines and herbal remedies have great potential for antimicrobial drug development and there has recently been a substantial increase in interest in this field. 35 The traditional Indian medicinal system Ayurveda uses a variety of natural plant and fruit products to treat numerous ailments. 3, 6, 7 Withania somnifera (L.) Dunal ( Figure 1 a; commonly known as ashwagandha) root has been used for thousands of years in Indian Ayuverda to treat a wide variety of conditions. 8 W. somnifera root is best known as an effective treatment for the promotion of physical and mental health, and a pharmacological basis exists for its use in the treatment of a variety of central nervous system disorders. 9 While it also appears to possess anti School of Environment and Science, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Queensland 4111, AUSTRALIA. 4 School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210046, CHINA. 
MATERIALS AND METHODS

Plant material and extraction
The Withania somnifera (L.) Dunal root powder used in this study was sourced from verified plants in India by Noodles Emporium (Australia) and supplied as a dried, ground powder. A voucher sample (NSC2017wsic) has been stored at the School of Environment and Science, Griffith University, Australia. Individual 1.5 g quantities of the material were weighed into separate tubes and 50 mL of methanol, deionised water, chloroform, hexane or ethyl acetate were added. All solvents were obtained from Ajax, Australia and were AR grade. The ground plant materials were individually extracted in each solvent for 24 hours at 
Qualitative phytochemical studies
Phytochemical analyses of the W. somnifera root extracts for the presence of saponins, phenolic compounds, flavonoids, phytosterols, triterpenoids, cardiac glycosides, anthraquinones, tannins and alkaloids were conducted by previously described assays. 18 
Antibiotics
PenicillinG (potency of 14401680 µg/mg), chloramphenicol (≥98 % purity by HPLC), erythromycin (potency ≥850 µg/mg), ciprofloxacin (≥98 % purity by HPLC), and tetracycline (≥95% purity by HPLC) were purchased from SigmaAldrich, Australia and were used as controls for the microplate liquid dilution assay. All antibiotics were prepared in sterile deionised water at stock concentrations of 0.01 mg/mL and stored at 4 o C until use. 
Bacterial cultures
Evaluation of antibacterial activity on agar
Antibacterial activity screening of the W. somnifera root extracts on solid agar was assessed using a modified disc diffusion assay method.
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Extracts (10 µL) were infused onto Whatman #1 filter discs (6 mm in diameter), with negative control discs containing 10 µL of extract solvent (1% DMSO). Penicillin, erythromycin, ciprofloxacin, tetracycline and chloramphenicol discs (1 µg) were prepared on discs and used as positive controls to compare antibacterial activity, while filter discs infused with 10 µL of distilled water were used as a negative control for the antibiotics.
Minimum inhibitory concentration (MIC) determination
The minimum inhibitory concentration for each extract was determined using a microplate liquid dilution MIC method, 5, 22 as it is generally consid ered the most sensitive bacterial growth inhibitory assay. Furthermore, as microplate liquid dilution MIC assays are perhaps the most commonly used method of quantifying bacterial growth inhibition efficacy, use of this method allows for comparisons with other studies. All microplates were incubated at 37°C for 24 h following addition of samples. pIodonitro tetrazolium violet (INT) was obtained from SigmaAldrich (Australia) and dissolved in sterile deionised water to produce a 0.2 mg/mL INT solution. A 40 µL volume of this solution was added into all wells and the plates were incubated for a further 6 hours at 2430°C. Following incuba tion, the MIC was visually determined as the lowest dose at which colour development was inhibited.
Fractional inhibitory concentration (FIC) assessment
Interactions between the W. somnifera root extracts and the conventional antibiotics were examined by determination of the sum of fractional inhibitory concentrations (ΣFIC) for each combination. 5 The FIC values for each component (a and b) were calculated using the following equa tions where a represents the plant extract sample and b represents the conventional antibiotic:
The ΣFIC was then calculated using the formula ΣFIC = FIC(a) + FIC(b). The interactions were classified as synergistic (ΣFIC ≤0.5), additive (ΣFIC >0.51.0), indifferent (ΣFIC >1.04.0) or antagonistic (ΣFIC >4.0).
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Artemia nauplii toxicity screening Potassium dichromate (K 2 Cr 2 O 7 ) (AR grade, ChemSupply, Australia) was prepared in deionised water (4 mg/mL) and serially diluted in arti ficial seawater for use as a reference toxin. Toxicity of the W. somnifera root extracts, the reference toxin and the conventional antibiotics was assessed using a modified Artemia franciscana nauplii lethality assay. 23, 24 The LC 50 with 95% confidence limits for each treatment was calculated using probit analysis.
Statistical analysis
Data are expressed as the mean ± SEM of at least three independent experiments. Oneway ANOVA was used to calculate differences be tween the control and treated groups, with a P value < 0.01 considered to be significant. 
RESULTS
Liquid extraction yields and qualitative phytochemical screening W. somnifera root extractions (1.5 g material) using various solvents yielded dried plant extracts ranging from 12 mg to 320 mg (Table 1) . Aqueous and methanolic extracts provided significantly greater yields of extracted material relative to the ethyl acetate, chloroform and hexane counterparts, which gave low to moderate yields. The dried extracts were resuspended in 10 mL of deionised water (containing 1 % DMSO), resulting in the concentrations presented in Table 1 . Qualitative phytochemical studies showed that methanol and water extracted the greatest amount, and widest range of, phytochemicals (Table 1) . These solvents extracted high levels of phenolic compounds and flavonoids, as well as moderate levels of saponins and low levels of tannins and triterpenoids. The ethyl acetate extracts generally extracted similar but lower phytochemical profiles as compared to the methanolic and aqueous extracts. In contrast, the chloroform and hexane extracts were generally devoid of detectable levels of all classes of the screened phytochemicals.
Antibacterial activity
To determine the ability of the crude plant extracts to inhibit the growth of the bacterial triggers of selected autoimmune inflammatory diseases, aliquots (10 µL) of each extract were screened using a disc diffusion assay. None of the W. somnifera extracts tested caused inhibition of the growth of the bacterial triggers of rheumatoid arthritis (P. mirabilis), ankylosing spondylitis (K. pneumoniae) and multiple sclerosis (A. baylyi and P. aeruginosa) (results not shown). In contrast, the methanolic and aqueous W. somnifera extracts were good inhibitors of bacterial triggers of rheumatic fever (S. pyogenes; Figure 2a ) and Hashimoto's disease (Y. enterocolitica; Figure 2b ) on solid agar, indicating that they may be useful in the prevention and treatment of these diseases.
Quantification of minimum inhibitory concentration (MIC)
The antimicrobial efficacies of the W. somnifera extracts were further quantified by determining the MIC values ( Table 2 ). The methanolic and aqueous extracts were particularly effective at inhibiting growth of Y. enterocolitica, with MIC values of 696 and 358 µg/mL, respectively. S. pyogenes growth was inhibited at MIC values of 6260 and 9690 µg/mL, respectively, for the methanolic and aqueous extracts, indicating a much weaker antimicrobial activity towards this strain as compared to Y. enterocolitica was found in liquid cultures.
Determination of combinational effects: Fractional inhibitory concentration (FIC) assessment
Fractional inhibitory concentration (FIC) determination was performed using a 1:1 ratio of each W. somnifera extract and conventional antibiotic and sums of FIC (ΣFIC) were calculated ( Table 3) . As all bacterial species were completely resistant to the ethyl acetate, chloroform and hexane extracts, no ΣFIC values could be determined for combinations containing these extracts. Similarly, as P. mirabilis, K. pneumonia, A. baylyi and P. aeruginosa were resistant to all extracts, no ΣFIC values could be determined for these bacteria. ΣFIC values were calculated for the remaining combinations and the class of interaction was determined for each. Additive interactions between the aqueous extract and penicillin or ciprofloxacin were observed against S. pyogenes, with an additive inter action also observed between the methanolic extract and ciprofloxacin for the same strain. A single combination produced an additive interac tion against Y. enterocolitica (methanolic extract with tetracycline) while three combinations were found to have an additive effect against S. pyogenes (methanolic extract with ciprofloxacin, and aqueous extracts with penicillin or ciprofloxacin). These are promising findings since the anti bacterial activity of these combinations is substantially enhanced against these strains, albeit not to the extent expected for a synergistic interaction. However, the additive growth inhibitory effects of such combinations show that they would be preferable as a growth inhibitor of these bacteria compared to treatment with the individual antibiotic or extract components. Of the remaining combinations, seven were determined to be noninter active. Whilst coadministering these extracts and antibiotics would be of no therapeutic benefit, they would not counteract/lessen the activity of the individual components and therefore may be deemed safe to use concomitantly. ΣFIC values could not be determined for the remaining interactive combinations (Table 3 ) except for an antagonistic interaction (ΣFIC > 4.0) between the aqueous W. somnifera extract and tetracycline. This suggests that this combination of extract and antibiotic significantly reduces the antimicrobial effect on Y. enterocolitica, indicating that this specific W. somnifera: antibiotic combination may need to be avoided to maintain antibacterial activity. Finally, no synergistic interactions (ΣFIC ≤ 0.5) were evident for any combination against any bacterial species.
Quantification of toxicity
All extracts were initially screened in the Artemia nauplii assay at 2000 µg/mL ( Figure 3) . Additionally, potassium dichromate was also tested in the bioassay as a reference toxin. The reference toxin was rapid in its onset of mortality, promoting nauplii death within the first 3 h of exposure, with 100% mortality evident within 5 h (data not shown).
The methanolic and aqueous extracts also induced 100% mortality following 24 h exposure. All other extracts induced <50% mortality and were therefore deemed to be nontoxic. To further quantify the effects of toxin concentration on the initiation of mortality, the methanolic and aqueous extracts were serially diluted in artificial seawater to test across Pharmacognosy Communications, Vol 8, Issue 2, Apr-Jun, 2018
Figure 3:
The lethality of the W. somnifera extracts (2000 µg/mL) and the potassium dichromate (1000 µg/mL) and seawater controls towards Artemia nauplii after 24 hours exposure. M = methanolic extract; W = aqueous extract; E = ethyl acetate extract; C = chloroform extract; H = hexane extract; NC = negative (seawater) control; PC = potassium dichromate control (1000 µg/mL). Results are expressed as mean % mortality ± SEM. Table 2 . No LC 50 are reported for the ethyl acetate, chloroform or hexane extracts as < 50 % mortality was seen in all tested concentrations. LC 50 values substantially >1000 μg/mL were determined for the methanolic and aqueous extracts. As extracts with LC 50 values >1000 μg/mL towards Artemia nauplii have been defined as being nontoxic in this assay, 23 each of the W. somnifera root extracts were deemed to be nontoxic.
DISCUSSION
W. somnifera is used in Ayuverda for a wide variety of therapeutic purposes. It is perhaps best known as a potent booster of the immune system, as a general tonic for wellbeing, and as a rejuvenative agent. 8 The root extracts also have documented uses for inhibiting bacterial growth and suppress the production of proinflammatory cytokines, thereby blocking inflammatory conditions, including arthritis, as reviewed else where. 25 Therefore, this study aimed to confirm the antibacterial activity of a panel of root extracts against bacterial species known to trigger autoimmune diseases in genetically susceptible individuals.
1417 Whilst we did detect some antibacterial activity in this study, most bacterial species examined were refractory to inhibition by the extracts. Only S. pyogenes and Y. enterocolitica were susceptible to inhibition by the methanolic and aqueous extracts, and the MIC values against S. pyogenes were indicative of only mild inhibitory activity. In contrast, the MIC val ues (358 and 696 μg/mL for the aqueous and methanolic extracts respec tively) against Y. enterocolitica indicated much greater potencies. The relatively low antibacterial strength determined in our study contrasts with several studies that have reported strong antibacterial activity for a variety of W. somnifera extracts. One publication reported potent inhibi tion of Salmonella typhimurium and Escherichia coli by W. somnifera leaf methanolic and hexane extracts. 26 However, the definition of potency in that study was based purely on the size of the zone of inhibition in disc diffusion assays. The authors did not evaluate the MIC values for the extracts, rendering a comparison of the potencies impossible. Further more, that study screened a single high concentration of each extract (100mg/mL). Inhibition at this concentration is not necessarily indica tive of high potency, and dose response studies are required. It is also noteworthy that this earlier study involved different bacterial species to those examined in the present study, which may also contribute to the differences. A more recent report by Alam et al. 27 examined a different panel of bacteria, including some of the species included in our study. That study reported large zones of inhibition against P. aeruginosa and K. pneumonia (approximately 2026 mm for the ethanolic extract). Whilst we did not prepare ethanolic extracts in our study, we did include methanolic extracts. These two solvents have similar polarity and can generally extract similar chemical constituents. The previous study 27 also determined MIC values and described the antibacterial activity as high based on these results. However, the MIC values reported for the W. somnifera root ethanolic extract were 50 mg/mL. These values would generally be regarded as inactive in most studies rather than the strong antibacterial activity which had been described in that report. Indeed, in our study, we class >10mg/mL as being inactive, 5<10mg/mL as low activity, 1<5 mg/mL as moderate activity and <1mg/mL as strong activity. If those criteria were used, the previously reported MIC values in the earlier study would instead be classed as inactive. The combinational studies involving extracts potentiating the activity of conventional antibiotics are perhaps of more interest. Several additive combinatorial interactions were noted. In particular, the water extract potentiated the activity of penicillin and ciprofloxacin against S. pyogenes. The methanolic extract potentiated ciprofloxacin against S. pyogenes and tetracycline against Y. enterocolitica. As such, these combinations would be beneficial against rheumatic fever and Hashimoto's disease, respectively, as they have greater efficacy than either component alone. Of the remaining combinations, the majority were either noninteractive, or were unable to be determined as at least one of the components in the combination showed no inhibition of bacterial growth when tested alone. Therefore, whilst using these combinations would have no addi tional therapeutic benefit, the components would not impede the activity of the other component. Notably, a single combination (aqueous extract in combination tetracycline) produced an antagonistic effect against Y. enterocolitica. This suggests that this combination should be avoided in the treatment of Hashimoto's disease (and any other diseases caused by this bacterium). Whilst a thorough examination of the phytochemical composition of the W. somnifera extracts was beyond the scope of this study, we detected high levels of flavonoids in the extracts that were found to exert anti bacterial effects. Flavonoids have previously been reported to have good growth inhibitory activity against a broad panel of pathogenic bacteria 2830 and it is likely that they may contribute to the potent bacterial growth inhibitory activity observed in our study. Other phytochemical classes may also contribute this activity. Saponins and triterpenes were also detected in the W. somnifera methanolic and aqueous extracts. This is consistent with previous studies which reported withanolides (Figure 1b) as abundant in similar extracts. 13 Some terpenoids have potent broad spectrum antibacterial activity 31 and it is therefore likely that they also contribute to the inhibition of the bacteria examined in our study. Further evaluation of the phytochemical composition and isolation of the active components is required to more rigorously assess the mechanism of bacterial growth inhibition. Of further note, all extracts displayed low toxicity in the Artemia nauplii bioassay. Indeed, LC 50 values ≥1000 µg/mL are generally deemed to be nontoxic for crude plant extracts. Only the methanolic and aqueous extracts induced any mortality and in both cases were substantially >1000 μg/mL. These findings are also consistent with studies which have demonstrated the W. somnifera root extracts to be nontoxic in rodents. 32, 33 Therefore, it is likely that the W. somnifera extracts are safe for both prophylactic and therapeutic use. However, further toxicity studies using mammalian cell lines are required to confirm the safety of these extracts.
CONCLUSION
The strong growth inhibitory activity of W. somnifera against Y. enterocolitica and its lack of toxicity render it a promising option for the prevention and treatment of Hashimoto's disease and any other infections of this bacterium. Further studies are required to isolate the compound(s) responsible for this activity and to elucidate the antibacterial mechanisms involved.
